Brian Stephenson, Ph.D., CFA, is a distinguished financial executive currently serving as the Chief Financial Officer (CFO) at BridgeBio Pharma Inc., a biopharmaceutical company focused on developing transformative medicines for genetic diseases and cancers. Dr. Stephenson's academic background is robust, with a Ph.D. in Chemistry from the University of California, Berkeley, which underscores his deep understanding of the scientific underpinnings of the pharmaceutical industry. He further enhanced his expertise by earning the Chartered Financial Analyst (CFA) designation, a testament to his proficiency in financial analysis and investment management. Before joining BridgeBio Pharma, Dr. Stephenson held several high-profile positions in the biotech and pharmaceutical sectors. He notably served as the CFO at Aimmune Therapeutics, where he played a pivotal role in guiding the company through its IPO and subsequent growth phases. His strategic financial leadership was instrumental in securing significant funding and partnerships that propelled Aimmune's development of innovative treatments for food allergies. Dr. Stephenson's career also includes key roles at companies like Proteolix, Inc., and Genentech, where he honed his skills in financial strategy and corporate development, contributing to successful product launches and acquisitions. As CFO at BridgeBio Pharma, Dr. Stephenson is responsible for overseeing the company's financial operations, including financial planning and analysis, accounting, and investor relations. His leadership has been crucial in navigating the complex financial landscape of drug development, ensuring that BridgeBio maintains a strong financial position to support its ambitious pipeline of therapies. Under his guidance, BridgeBio has successfully raised capital through various financing rounds and strategic partnerships, positioning the company for sustained growth and the potential to bring life-changing treatments to patients worldwide. Dr. Stephenson's blend of scientific knowledge and financial acumen makes him an invaluable asset to BridgeBio Pharma as it continues its mission to bridge the gap between genetic discoveries and patient care.